Erik Roelofs
Overview
Explore the profile of Erik Roelofs including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
2934
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Paulissen J, Zegers C, Nijsten I, Reiters P, Houben R, Eekers D, et al.
Tech Innov Patient Support Radiat Oncol
. 2022 Nov;
24:107-112.
PMID: 36387779
Mobile health data capture applications (mHDA's) may improve communication between healthcare providers and patients. However, there is limited literature about the use of mHDA's facilitating clinical trials. In this study,...
2.
Kothe A, Lomax A, Giovannelli A, Safai S, Bizzocchi N, Roelofs E, et al.
Radiother Oncol
. 2022 Oct;
176:208-214.
PMID: 36228759
Background And Purpose: To investigate the impact of organ motion on hypoxia-guided proton therapy treatments for non-small cell lung cancer (NSCLC) patients. Materials And Methods: Hypoxia PET and 4D imaging...
3.
De Roeck L, van der Weide H, Eekers D, Kramer M, Alapetite C, Blomstrand M, et al.
Radiother Oncol
. 2022 Jan;
168:241-249.
PMID: 35093408
Purpose: Treatment-related toxicity after irradiation of brain tumours has been underreported in the literature. Furthermore, there is considerable heterogeneity on how and when toxicity is evaluated. The aim of this...
4.
Eekers D, Di Perri D, Roelofs E, Postma A, Dijkstra J, Ajithkumar T, et al.
Radiother Oncol
. 2021 May;
160:259-265.
PMID: 34015385
Background And Purpose: To update the digital online atlas for organs at risk (OARs) delineation in neuro-oncology based on high-quality computed tomography (CT) and magnetic resonance (MR) imaging with new...
5.
t Ven L, Roelofs E, Cubillos Mesias M, Compter I, Klaver Y, Smeenk R, et al.
Clin Transl Radiat Oncol
. 2021 Mar;
28:32-38.
PMID: 33748441
Background And Purpose: Proton therapy is expected to outperform photon-based treatment regarding organs at risk (OAR) sparing but to date there is no method to practically measure clinical benefit. Here,...
6.
Bellezzo M, Fonseca G, Voncken R, Verrijssen A, van Beveren C, Roelofs E, et al.
Brachytherapy
. 2020 May;
19(4):544-553.
PMID: 32386884
Purpose: Dose escalation yields higher complete response to rectal tumors, which may enable the omission of surgery. Dose escalation using 50 kVp contact x-ray brachytherapy (CXB) allow the treatment of...
7.
Troost E, Wink K, Roelofs E, Simone 2nd C, Makocki S, Lock S, et al.
Br J Radiol
. 2019 Dec;
93(1107):20190879.
PMID: 31804145
Objective: Locally recurrent disease is of increasing concern in (non-)small cell lung cancer [(N)SCLC] patients. Local reirradiation with photons or particles may be of benefit to these patients. In this...
8.
Twisk D, Wesseling S, Vlakveld W, Vissers J, Hegeman G, Hukker N, et al.
J Safety Res
. 2018 Dec;
67:137-143.
PMID: 30553416
Introduction: In the Netherlands, young cyclists are extremely vulnerable in traffic, which may partly be due to their still underdeveloped higher-order cycling skill. So far, knowledge on their actual level...
9.
Eekers D, Roelofs E, Cubillos-Mesias M, Niel C, Smeenk R, Hoeben A, et al.
Acta Oncol
. 2018 Nov;
58(1):57-65.
PMID: 30474448
Background And Purpose: Patients with low-grade glioma (LGG) have a prolonged survival expectancy due to better discriminative tumor classification and multimodal treatment. Consequently, long-term treatment toxicity gains importance. Contemporary radiotherapy...
10.
Lambrecht M, Eekers D, Alapetite C, Burnet N, Calugaru V, Coremans I, et al.
Radiother Oncol
. 2018 May;
128(1):26-36.
PMID: 29779919
Purpose: For unbiased comparison of different radiation modalities and techniques, consensus on delineation of radiation sensitive organs at risk (OARs) and on their dose constraints is warranted. Following the publication...